Derik De Bruin
Stock Analyst at B of A Securities
(3.56)
# 691
Out of 5,182 analysts
206
Total ratings
64.08%
Success rate
13.66%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $21 → $30 | $21.37 | +40.38% | 10 | Apr 20, 2026 | |
| WAT Waters | Maintains: Neutral | $410 → $350 | $300.73 | +16.38% | 15 | Feb 10, 2026 | |
| BRKR Bruker | Maintains: Buy | $43 → $60 | $36.26 | +65.47% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $114.87 | +43.64% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,262.48 | +10.10% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $178.98 | +22.92% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $54.29 | -50.27% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $85.18 | +29.14% | 3 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $34.02 | +48.38% | 6 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $4.84 | +127.27% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $9.02 | +77.38% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $470.22 | +40.36% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $158.98 | +47.82% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $166.79 | +25.91% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $292.13 | +21.52% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $16.21 | +60.39% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $259.57 | +4.40% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $195.05 | -6.69% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $10.76 | +95.17% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $12.24 | +161.44% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $126.92 | -21.21% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $2.98 | +336.24% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.93 | +236.79% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $102.49 | +153.68% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $7.85 | +1,428.66% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $116.65 | +2.87% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.20 | +309.09% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $568.30 | -58.65% | 3 | Nov 2, 2018 |
10x Genomics
Apr 20, 2026
Maintains: Neutral
Price Target: $21 → $30
Current: $21.37
Upside: +40.38%
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $410 → $350
Current: $300.73
Upside: +16.38%
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $36.26
Upside: +65.47%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $114.87
Upside: +43.64%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,262.48
Upside: +10.10%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $178.98
Upside: +22.92%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $54.29
Upside: -50.27%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $85.18
Upside: +29.14%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $34.02
Upside: +48.38%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $4.84
Upside: +127.27%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $9.02
Upside: +77.38%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $470.22
Upside: +40.36%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $158.98
Upside: +47.82%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $166.79
Upside: +25.91%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $292.13
Upside: +21.52%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $16.21
Upside: +60.39%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $259.57
Upside: +4.40%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $195.05
Upside: -6.69%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $10.76
Upside: +95.17%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $12.24
Upside: +161.44%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $126.92
Upside: -21.21%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $2.98
Upside: +336.24%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.93
Upside: +236.79%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $102.49
Upside: +153.68%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $7.85
Upside: +1,428.66%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $116.65
Upside: +2.87%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.20
Upside: +309.09%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $568.30
Upside: -58.65%